Positive results for Avexa
Monday, 16 March, 2009
Melbourne biotech Avexa has reported positive results from its ongoing Phase IIb trial of apricitabine (ATC) in patients with HIV.
Apricitabine is also in Phase III trials for HIV patients with resistance to common antiretrovirals. Interim results in this trial are expected shortly.
The Phase IIb trial is an open label trial for people who have failed previous HIV treatments such as 3TC. After almost two years on the trial, no resistance to ATC has been identified and no serious adverse events have been reported.
Over 85 per cent of patients have HIV loads below detectable levels and CD4 cells on average were over 500 microlitres, the company said.
Less penicillin needed to treat Strep A infection than we thought
It's never been known exactly how much penicillin prevents sore throats — the most...
Stress disrupts emotion control in mental illness
Acute stress may impair key brain functions involved in managing emotions — particularly in...
Organoid platform enables closer study of bat-borne viruses
Reconstructing bat organ physiology in the lab lets scientists explore how zoonotic viruses work...
